NASDAQ:XRTX

XORTX Therapeutics Q4 2025 Earnings Results & Report

XORTX Therapeutics logo
$0.84 -0.05 (-5.73%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$0.84 0.00 (0.00%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

XORTX Therapeutics reported Q4 2025 earnings on February 26, 2026. The company reported EPS of -$0.45.

Earnings Announcement Details

Quarter
Q4 2025
Time
After Market Closes

XORTX Therapeutics EPS Results

Actual EPS
-$0.45
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

XORTX Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

XORTX Therapeutics Q4 2025 Earnings FAQ

XORTX Therapeutics (NASDAQ:XRTX) reported earnings of -$0.45 per share for Q4 2025. The report was announced on Thursday, February 26, 2026.

XORTX Therapeutics Earnings Headlines

XORTX Hikes on Revealing Drug Supply
XORTX Completes Manufacturing of Clinical Drug Supply
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
XORTX Therapeutics Inc XRTX
See More XORTX Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like XORTX Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on XORTX Therapeutics and other key companies, straight to your email.

About XORTX Therapeutics

XORTX Therapeutics (NASDAQ:XRTX) is a clinical-stage biotechnology company headquartered in Calgary, Alberta. It develops treatments for progressive kidney diseases, with a focus on conditions that can lead to declining kidney function.

The company’s research programs include XRx-008 for autosomal dominant polycystic kidney disease, XRx-101 for acute kidney injury, and XRx-225 for diabetic nephropathy. These programs are investigational and are not marketed therapies.

XORTX’s approach focuses on purine metabolism and the enzyme xanthine oxidase, which the company is studying as a target for reducing processes associated with kidney injury and disease progression.

View XORTX Therapeutics Profile